Skip to main content
Top
Published in: Journal of Gastroenterology 7/2018

01-07-2018 | Original Article—Liver, Pancreas, and Biliary Tract

Independent association between prediabetes and future pancreatic fat accumulation: a 5-year Japanese cohort study

Authors: Hajime Yamazaki, Shinichi Tauchi, Miho Kimachi, Mitsuru Dohke, Nagisa Hanawa, Yoshihisa Kodama, Akio Katanuma, Yosuke Yamamoto, Shunichi Fukuhara, Shingo Fukuma

Published in: Journal of Gastroenterology | Issue 7/2018

Login to get access

Abstract

Background

The association between pancreatic fat and glucose dysmetabolism has been reported in several cross-sectional studies; however, a recent longitudinal study showed that baseline pancreatic fat did not cause subsequent diabetes mellitus. We hypothesized that pancreatic fat is not a cause but a manifestation of glucose dysmetabolism and aimed to investigate the association between baseline prediabetes and future pancreatic fat accumulation.

Methods

Between 2008 and 2015, 198 nondiabetic participants, who underwent a health check-up via unenhanced computed tomography (CT) twice with CT intervals ≥ 5 years, were enrolled as prediabetes (n = 48) and non-prediabetes participants (n = 150). Prediabetes was defined as fasting plasma glucose of 100–125 mg/dl or hemoglobin A1c of 5.7–6.4%. Pancreatic fat was evaluated using a histologically validated method to measure the difference between pancreas and spleen attenuations (P–S) on CT. Pancreatic fat accumulation during follow-up was measured as P–S change from baseline. Multiple linear regression was used to evaluate the association between baseline prediabetes and future pancreatic fat accumulation with adjustment for age, sex, body mass index, physical activity, and liver fat at baseline.

Results

Mean pancreatic fat accumulation was 0.30 (SD, 5.8) Hounsfield units during follow-up. On univariate analysis, baseline prediabetes was associated with future pancreatic fat accumulation (β = 3.73; 95% CI 1.91–5.55; P < 0.001). This association remained statistically significant on multivariate analysis (β = 3.14; 95% CI 1.25–5.03; P = 0.001).

Conclusions

Prediabetes is a risk factor for future pancreatic fat accumulation. Pancreatic fat may be a manifestation of glucose dysmetabolism.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Wong VW, Wong GL, Yeung DK, et al. Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109(4):589–97.CrossRefPubMed Wong VW, Wong GL, Yeung DK, et al. Fatty pancreas, insulin resistance, and beta-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109(4):589–97.CrossRefPubMed
4.
go back to reference Singh RG, Yoon HD, Wu LM, et al. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1–13.CrossRefPubMed Singh RG, Yoon HD, Wu LM, et al. Ectopic fat accumulation in the pancreas and its clinical relevance: a systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1–13.CrossRefPubMed
5.
go back to reference Wang H, Maitra A, Wang H. Obesity, intrapancreatic fatty infiltration, and pancreatic cancer. Clin Cancer Res. 2015;21(15):3369–71.CrossRefPubMed Wang H, Maitra A, Wang H. Obesity, intrapancreatic fatty infiltration, and pancreatic cancer. Clin Cancer Res. 2015;21(15):3369–71.CrossRefPubMed
6.
go back to reference Rebours V, Gaujoux S, d’Assignies G, et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res. 2015;21(15):3522–8.CrossRefPubMed Rebours V, Gaujoux S, d’Assignies G, et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res. 2015;21(15):3522–8.CrossRefPubMed
7.
go back to reference Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5:e53.CrossRefPubMedPubMedCentral Hori M, Takahashi M, Hiraoka N, et al. Association of pancreatic fatty infiltration with pancreatic ductal adenocarcinoma. Clin Transl Gastroenterol. 2014;5:e53.CrossRefPubMedPubMedCentral
8.
go back to reference Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol. 2011;8(3):169–77.CrossRefPubMed Smits MM, van Geenen EJ. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol. 2011;8(3):169–77.CrossRefPubMed
10.
go back to reference Steven S, Hollingsworth KG, Small PK, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care. 2016;39(1):158–65.CrossRefPubMed Steven S, Hollingsworth KG, Small PK, et al. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care. 2016;39(1):158–65.CrossRefPubMed
11.
go back to reference Kim SY, Kim H, Cho JY, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014;271(1):104–12.CrossRefPubMed Kim SY, Kim H, Cho JY, et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology. 2014;271(1):104–12.CrossRefPubMed
12.
go back to reference Yamazaki H, Tsuboya T, Katanuma A, et al. Lack of independent association between fatty pancreas and incidence of type 2 diabetes: 5-year Japanese cohort study. Diabetes Care. 2016;39(10):1677–83.CrossRefPubMed Yamazaki H, Tsuboya T, Katanuma A, et al. Lack of independent association between fatty pancreas and incidence of type 2 diabetes: 5-year Japanese cohort study. Diabetes Care. 2016;39(10):1677–83.CrossRefPubMed
13.
go back to reference Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism. 2007;56(10):1418–24.CrossRefPubMed Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism. 2007;56(10):1418–24.CrossRefPubMed
15.
go back to reference Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212–28.CrossRefPubMedPubMedCentral Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212–28.CrossRefPubMedPubMedCentral
16.
go back to reference Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med. 2016;164(8):542–52.CrossRefPubMed Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association standards of medical care in diabetes. Ann Intern Med. 2016;164(8):542–52.CrossRefPubMed
17.
go back to reference Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105–12.CrossRefPubMed Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105–12.CrossRefPubMed
18.
go back to reference Glymour MM, Weuve J, Berkman LF, et al. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005;162(3):267–78.CrossRefPubMed Glymour MM, Weuve J, Berkman LF, et al. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005;162(3):267–78.CrossRefPubMed
19.
go back to reference van der Zijl NJ, Goossens GH, Moors CC, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab. 2011;96(2):459–67.CrossRefPubMed van der Zijl NJ, Goossens GH, Moors CC, et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on beta-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab. 2011;96(2):459–67.CrossRefPubMed
20.
go back to reference Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013;12:77.CrossRefPubMedPubMedCentral Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013;12:77.CrossRefPubMedPubMedCentral
21.
go back to reference Mathur A, Pitt HA, Marine M, et al. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg. 2007;246(6):1058–64.CrossRefPubMed Mathur A, Pitt HA, Marine M, et al. Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg. 2007;246(6):1058–64.CrossRefPubMed
22.
go back to reference Majumder S, Philip NA, Takahashi N, et al. Fatty pancreas: should we be concerned? Pancreas. 2017;46(10):1251–8.CrossRefPubMed Majumder S, Philip NA, Takahashi N, et al. Fatty pancreas: should we be concerned? Pancreas. 2017;46(10):1251–8.CrossRefPubMed
23.
go back to reference Khoury T, Asombang AW, Berzin TM, et al. The clinical implications of fatty pancreas: a concise review. Dig Dis Sci. 2017;62(10):2658–67.CrossRefPubMed Khoury T, Asombang AW, Berzin TM, et al. The clinical implications of fatty pancreas: a concise review. Dig Dis Sci. 2017;62(10):2658–67.CrossRefPubMed
24.
go back to reference Catanzaro R, Cuffari B, Italia A, et al. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol. 2016;22(34):7660–75.CrossRefPubMedPubMedCentral Catanzaro R, Cuffari B, Italia A, et al. Exploring the metabolic syndrome: nonalcoholic fatty pancreas disease. World J Gastroenterol. 2016;22(34):7660–75.CrossRefPubMedPubMedCentral
25.
go back to reference Navina S, Acharya C, DeLany JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med. 2011;3(107):107ra10.CrossRef Navina S, Acharya C, DeLany JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med. 2011;3(107):107ra10.CrossRef
26.
go back to reference Kabeya Y, Kato M, Isogawa A, et al. Descriptive epidemiology of diabetes prevalence and HbA1c distributions based on a self-reported questionnaire and a health checkup in the JPHC diabetes study. J Epidemiol. 2014;24(6):460–8.CrossRefPubMed Kabeya Y, Kato M, Isogawa A, et al. Descriptive epidemiology of diabetes prevalence and HbA1c distributions based on a self-reported questionnaire and a health checkup in the JPHC diabetes study. J Epidemiol. 2014;24(6):460–8.CrossRefPubMed
28.
go back to reference Le KA, Ventura EE, Fisher JQ, et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care. 2011;34(2):485–90.CrossRefPubMedPubMedCentral Le KA, Ventura EE, Fisher JQ, et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care. 2011;34(2):485–90.CrossRefPubMedPubMedCentral
29.
go back to reference Saisho Y, Butler AE, Meier JJ, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007;20(8):933–42.CrossRefPubMedPubMedCentral Saisho Y, Butler AE, Meier JJ, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007;20(8):933–42.CrossRefPubMedPubMedCentral
Metadata
Title
Independent association between prediabetes and future pancreatic fat accumulation: a 5-year Japanese cohort study
Authors
Hajime Yamazaki
Shinichi Tauchi
Miho Kimachi
Mitsuru Dohke
Nagisa Hanawa
Yoshihisa Kodama
Akio Katanuma
Yosuke Yamamoto
Shunichi Fukuhara
Shingo Fukuma
Publication date
01-07-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 7/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1422-2

Other articles of this Issue 7/2018

Journal of Gastroenterology 7/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.